Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...

Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery through innovative technology ...

The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

CAR-T cell therapy provides long, treatment-free remissions for relapsed multiple myeloma, using genetically modified T cells ...

Colleen Mabasa, a patient with multiple myeloma, discusses her CAR T-cell therapy journey and the pivotal role self-advocacy ...

Universal CAR T cells produce rapid remissions and enable allogeneic stem cell transplants in patients with relapsed or refractory T-cell acute lymphoblastic leukemia.

Improved QOL is observed in patients over two years post-infusion and those without disease progression, highlighting the ...

A blood cancer diagnosis comes with a lot of new information and confusion ranging from blood tests and medical terminology to healthcare provider conversations and treatment considerations. Here’s ...

Immune cells are most commonly engineered to kill cancers, but now, scientists have shown the technique makes the gut lining ...

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

For the first time, researchers at the University of British Columbia have demonstrated how to reliably produce an important ...